72 episodes
Life Science Today Noah Goodson, PhD
-
- Science
-
-
5.0 • 7 Ratings
-
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
-
Final Episode
This week, I have an announcement to make.
Find out more at
https://LifeScienceTodayPodcast.com
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. -
Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago
Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Sanofi/Takeda
UniQure & CSL
Fog Pharma
Merck + Imago
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. -
Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Provention
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. -
Intellia, Regeneron, Viatris + Oyster Point
More CRISPR data, oncology wins, and a new player in ophthalmology
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Intellia
Regeneron
Viatris + Oyster Point
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. -
Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye
Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for others
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Sumitovant + Myovant
Thermo Fisher + Binding Site Group
Astellas & Taysha
Agios
Vaxctye
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. -
FDA, AbbVie + DJS, Roche + Hookipa, Kyverna
Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future.
Find out more at
https://LifeScienceTodayPodcast.com
Story References
FDA
AbbVie + DJS
Roche + Hookipa
Kyverna
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Customer Reviews
Brilliant insights
Dr. Goodson holds your attention brilliantly through clear and direct information without sacrificing substance. His expertise is on display each episode through sound explanations of complex movements within the biotech and pharmaceutical worlds. This podcast is perfect for the novice as well as expert relating to these topics of discussion. I highly recommend this be a regular in your podcast rotation!
Not only informative but also entertaining!
Dr Goodson brilliantly delivers scientific updates in a manner absent of confusing jargon, making it approachable to everyone. He also injects a bit of his educational discernment but still remains neutral. The short updates are perfect and I'm looking forward to more.
to the point
speaker is clear, easy to understand, length is good, content relevant. ads not intrusive